• Active, not recruiting

NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma

Updated: Sep 29

MCARH109 CART

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

MCARH109

This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment. The study treatment could stop the growth of the cancer, but it could also cause side effects.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT04555551

Official Title: Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

First Posted : September 18, 2020

Click here for details on ClinicalTrials.gov

 

autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109

 

GPRC5D-Targeted CAR T Cells for Myeloma

N Engl J Med; 2022 Sep 29

Conclusions: The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).

Learn more

 

827 Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 704. Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Therapies, Lymphoid Malignancies

Monday, December 13, 2021: 5:30 PM

Learn more

 

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma

Blood Cancer Discov;2020 Sep

Learn more

 

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Sci Transl Med;2019 Mar 27

Learn more

 

- CART

- MCARH109

 

- New York: Memorial Sloan-Kettering Cancer Center New York

 

Location

United States, New York

 

RELATED GPRC5D POSTS


NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS

Click here for details


NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Click here for details


NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia

Click here for details


NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

Click here for details

 

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details






Posts Archive